Single Administration of KBSA301 in Patients with Severe Pneumonia.

• Research type

  Research Study

• Full title

  A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Group Study to assess the Safety, Tolerability, Pharmacokinetics, Efficacy and Pharmacodynamics of a Single Intravenous Administration of KBSA301 in Severe Pneumonia caused by Staphylococcus aureus

• IRAS ID

  97213

• Contact name

  Barbara Philips

• Contact email

  bphilips@sgul.ac.uk

• Sponsor organisation

  Kenta Biotech Ltd

• Eudract number

  2011-005268-43

• ISRCTN Number

  n.a

• Clinicaltrials.gov Identifier

  n.a

• Research summary

  The main purpose of this study is to assess the safety and tolerability of single ascending doses of KBSA301 in patients with severe pneumonia caused by S. aureus and treated with standard S. aureus antibiotic therapy.

• REC name

  East of England - Cambridge East Research Ethics Committee

• REC reference

  12/EE/0127

• Date of REC Opinion

  24 May 2012

• REC opinion

  Further Information Favourable Opinion